Orange Book product · Generic (ANDA)
RIVASTIGMINE
RIVASTIGMINE
Generic (ANDA)ANDA 215445TE ABRX YICHANG HUMANWELL
At a glance
Sep 23, 2025
Approved
Generic (ANDA)
Application
AB
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Sep 23, 2025
9 mo ago
Today
Pharmaceutical detail
Active ingredient
RIVASTIGMINE
Strength
4.6MG/24HR
Dosage form
FILM, EXTENDED RELEASE
Route
TRANSDERMAL
TE code
AB
Application
ANDA 215445
Product number
001
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of RIVASTIGMINE
- 2007EXELONBrand (NDA)
NDA 022083 · SANDOZ
- 2019RIVASTIGMINEGeneric (ANDA)
ANDA 209063 · BRECKENRIDGE
- 2019RIVASTIGMINEGeneric (ANDA)
ANDA 206318 · ZYDUS PHARMS
- 2019RIVASTIGMINEGeneric (ANDA)
ANDA 207308 · AMNEAL PHARMS
- 2018RIVASTIGMINEGeneric (ANDA)
ANDA 205622 · MYLAN TECHNOLOGIES
- 2015RIVASTIGMINEGeneric (ANDA)
ANDA 204403 · ALVOGEN
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
